Episode 51. Venetoclax in AML with Dr. Andrew Wei
Blood Cancer Talks
00:00
Venetoclax Resistance and Trials in AML
This chapter examines venetoclax resistance in acute myeloid leukemia (AML), particularly in the monocytic subtype and the role of MCL1 and BCLXL proteins. It reviews a phase 2B trial comparing venetoclax with traditional treatments for younger patients and discusses the implications for clinical practice and future studies. Furthermore, it highlights ongoing research, including the Intercept trial aimed at exploring treatment options for minimal residual disease in AML patients.
Transcript
Play full episode
